Cargando…

Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature

BACKGROUND: This study aimed to analyze the clinical and pathological features of extrauterine endometrial stromal sarcoma (EESS) and explore an effective therapeutic regimen to reduce the recurrence rate in low-grade EESS patients. METHODS: Ten LG-EESS patients who were treated at the Chinese Acade...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, You, Li, Nan, Zhang, Rong, Bai, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759284/
https://www.ncbi.nlm.nih.gov/pubmed/35027071
http://dx.doi.org/10.1186/s12957-021-02474-1
_version_ 1784633078482731008
author Wu, You
Li, Nan
Zhang, Rong
Bai, Ping
author_facet Wu, You
Li, Nan
Zhang, Rong
Bai, Ping
author_sort Wu, You
collection PubMed
description BACKGROUND: This study aimed to analyze the clinical and pathological features of extrauterine endometrial stromal sarcoma (EESS) and explore an effective therapeutic regimen to reduce the recurrence rate in low-grade EESS patients. METHODS: Ten LG-EESS patients who were treated at the Chinese Academy of Medical Sciences Cancer Institute and Hospital from June 1999 to June 2019 were collected and analyzed. RESULTS: (1) Patient demographics are summarized in manuscript. Preoperative CA125 examination showed that 8 patients had a median level of 49.5 U/L (15.4–168.0 U/L). (2) All ten patients underwent tumor cytoreductive surgery. Five patients underwent optimal tumor resection and achieved an R0 resection. After the initial surgery, 7 patients who had multiple metastasis were treated with adjuvant chemotherapy, 2 patients with vaginal ESS were treated with chemotherapy and radiation therapy, and 6 patients with ER/PR positive received hormone therapy with or without chemotherapy. (2) Most EESS patients had multiple tumors. The omentum was the most commonly affected site, followed by the ovaries. (3) The median follow-up was 94 (range: 27–228) months, and recurrence was observed in 3 patients (n = 10, 30%) who underwent non-optimal surgery and no hormone therapy. The 5-year and 10-year DFS rates were both 70%, as shown in Fig. 2. OS was both 100% at 5 and 10 years. CONCLUSION: As a conclusion, EESS is a rare disease and LG-EESS has a good prognosis. Surgery remains the available treatment for patients. LG-EESS has a risk of late recurrence which requires a long-term follow-up. With a limited sample size, our study shows optimal tumor reductive surgery and adjuvant hormone therapy may significantly reduce the risk of recurrence.
format Online
Article
Text
id pubmed-8759284
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87592842022-01-18 Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature Wu, You Li, Nan Zhang, Rong Bai, Ping World J Surg Oncol Research BACKGROUND: This study aimed to analyze the clinical and pathological features of extrauterine endometrial stromal sarcoma (EESS) and explore an effective therapeutic regimen to reduce the recurrence rate in low-grade EESS patients. METHODS: Ten LG-EESS patients who were treated at the Chinese Academy of Medical Sciences Cancer Institute and Hospital from June 1999 to June 2019 were collected and analyzed. RESULTS: (1) Patient demographics are summarized in manuscript. Preoperative CA125 examination showed that 8 patients had a median level of 49.5 U/L (15.4–168.0 U/L). (2) All ten patients underwent tumor cytoreductive surgery. Five patients underwent optimal tumor resection and achieved an R0 resection. After the initial surgery, 7 patients who had multiple metastasis were treated with adjuvant chemotherapy, 2 patients with vaginal ESS were treated with chemotherapy and radiation therapy, and 6 patients with ER/PR positive received hormone therapy with or without chemotherapy. (2) Most EESS patients had multiple tumors. The omentum was the most commonly affected site, followed by the ovaries. (3) The median follow-up was 94 (range: 27–228) months, and recurrence was observed in 3 patients (n = 10, 30%) who underwent non-optimal surgery and no hormone therapy. The 5-year and 10-year DFS rates were both 70%, as shown in Fig. 2. OS was both 100% at 5 and 10 years. CONCLUSION: As a conclusion, EESS is a rare disease and LG-EESS has a good prognosis. Surgery remains the available treatment for patients. LG-EESS has a risk of late recurrence which requires a long-term follow-up. With a limited sample size, our study shows optimal tumor reductive surgery and adjuvant hormone therapy may significantly reduce the risk of recurrence. BioMed Central 2022-01-13 /pmc/articles/PMC8759284/ /pubmed/35027071 http://dx.doi.org/10.1186/s12957-021-02474-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, You
Li, Nan
Zhang, Rong
Bai, Ping
Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title_full Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title_fullStr Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title_full_unstemmed Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title_short Primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
title_sort primary low-grade extrauterine endometrial stromal sarcoma: analysis of 10 cases with a review of the literature
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759284/
https://www.ncbi.nlm.nih.gov/pubmed/35027071
http://dx.doi.org/10.1186/s12957-021-02474-1
work_keys_str_mv AT wuyou primarylowgradeextrauterineendometrialstromalsarcomaanalysisof10caseswithareviewoftheliterature
AT linan primarylowgradeextrauterineendometrialstromalsarcomaanalysisof10caseswithareviewoftheliterature
AT zhangrong primarylowgradeextrauterineendometrialstromalsarcomaanalysisof10caseswithareviewoftheliterature
AT baiping primarylowgradeextrauterineendometrialstromalsarcomaanalysisof10caseswithareviewoftheliterature